| Abhishek Gowda, MD | |
|
429 Llewellyn Ave, Campbell, CA 95008-1948 | |
| (408) 364-1616 | |
| (408) 378-6775 |
| Full Name | Abhishek Gowda |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 15 Years |
| Location | 429 Llewellyn Ave, Campbell, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710114772 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| San Mateo Medical Center | San mateo, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| County Of San Mateo | 9032023171 | 242 |
| Spine And Sports Medical Group Inc | 5799707782 | 3 |
News Archive
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).
A new discovery about how cells move inside the body may provide scientists with crucial information about disease mechanisms such as the spread of cancer or the constriction of airways caused by asthma.
Eli Lilly and Company today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42.
Children and adolescents with multisystem inflammatory syndrome in children (MIS-C) who are treated initially with intravenous immune globulin (IVIG) and glucocorticoids have reduced risk for serious short-term outcomes, including cardiovascular dysfunction, than those who receive an initial treatment of IVIG alone, a new study finds.
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI 61 trial presented today in a Hot Line Session at ESC Congress and published in the New England Journal of Medicine.
› Verified 9 days ago
| Entity Name | County Of San Mateo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679642326 PECOS PAC ID: 9032023171 Enrollment ID: O20031126000292 |
News Archive
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).
A new discovery about how cells move inside the body may provide scientists with crucial information about disease mechanisms such as the spread of cancer or the constriction of airways caused by asthma.
Eli Lilly and Company today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42.
Children and adolescents with multisystem inflammatory syndrome in children (MIS-C) who are treated initially with intravenous immune globulin (IVIG) and glucocorticoids have reduced risk for serious short-term outcomes, including cardiovascular dysfunction, than those who receive an initial treatment of IVIG alone, a new study finds.
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI 61 trial presented today in a Hot Line Session at ESC Congress and published in the New England Journal of Medicine.
› Verified 9 days ago
| Entity Name | County Of San Mateo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831268580 PECOS PAC ID: 9032023171 Enrollment ID: O20040123000822 |
News Archive
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).
A new discovery about how cells move inside the body may provide scientists with crucial information about disease mechanisms such as the spread of cancer or the constriction of airways caused by asthma.
Eli Lilly and Company today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42.
Children and adolescents with multisystem inflammatory syndrome in children (MIS-C) who are treated initially with intravenous immune globulin (IVIG) and glucocorticoids have reduced risk for serious short-term outcomes, including cardiovascular dysfunction, than those who receive an initial treatment of IVIG alone, a new study finds.
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI 61 trial presented today in a Hot Line Session at ESC Congress and published in the New England Journal of Medicine.
› Verified 9 days ago
| Entity Name | Spine & Sports Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023186004 PECOS PAC ID: 5799707782 Enrollment ID: O20051219000507 |
News Archive
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).
A new discovery about how cells move inside the body may provide scientists with crucial information about disease mechanisms such as the spread of cancer or the constriction of airways caused by asthma.
Eli Lilly and Company today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42.
Children and adolescents with multisystem inflammatory syndrome in children (MIS-C) who are treated initially with intravenous immune globulin (IVIG) and glucocorticoids have reduced risk for serious short-term outcomes, including cardiovascular dysfunction, than those who receive an initial treatment of IVIG alone, a new study finds.
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI 61 trial presented today in a Hot Line Session at ESC Congress and published in the New England Journal of Medicine.
› Verified 9 days ago
| Entity Name | Alpana Gowda Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215315080 PECOS PAC ID: 9830404425 Enrollment ID: O20150811005065 |
News Archive
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).
A new discovery about how cells move inside the body may provide scientists with crucial information about disease mechanisms such as the spread of cancer or the constriction of airways caused by asthma.
Eli Lilly and Company today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42.
Children and adolescents with multisystem inflammatory syndrome in children (MIS-C) who are treated initially with intravenous immune globulin (IVIG) and glucocorticoids have reduced risk for serious short-term outcomes, including cardiovascular dysfunction, than those who receive an initial treatment of IVIG alone, a new study finds.
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI 61 trial presented today in a Hot Line Session at ESC Congress and published in the New England Journal of Medicine.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Abhishek Gowda, MD 300 Berry St Unit 813, San Francisco, CA 94158-1666 Ph: () - | Abhishek Gowda, MD 429 Llewellyn Ave, Campbell, CA 95008-1948 Ph: (408) 364-1616 |
News Archive
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).
A new discovery about how cells move inside the body may provide scientists with crucial information about disease mechanisms such as the spread of cancer or the constriction of airways caused by asthma.
Eli Lilly and Company today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42.
Children and adolescents with multisystem inflammatory syndrome in children (MIS-C) who are treated initially with intravenous immune globulin (IVIG) and glucocorticoids have reduced risk for serious short-term outcomes, including cardiovascular dysfunction, than those who receive an initial treatment of IVIG alone, a new study finds.
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI 61 trial presented today in a Hot Line Session at ESC Congress and published in the New England Journal of Medicine.
› Verified 9 days ago
John Erskine Welsh, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 429 Llewellyn Ave, Campbell, CA 95008 Phone: 408-364-1616 | |
Reshmi Rajan, Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 163 E Hamilton Ave, Campbell, CA 95008 Phone: 408-866-5567 Fax: 408-866-5567 | |
Dr. Sherman Nam Tran, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 429 Llewellyn Ave, Campbell, CA 95008 Phone: 408-364-1616 Fax: 408-378-6775 | |
Laura Darnell, PT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2327 Montezuma Dr, Campbell, CA 95008 Phone: 408-373-4189 | |
Mikiko Murakami, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 429 Llewellyn Ave, Campbell, CA 95008 Phone: 408-364-1616 | |
Maliheh Massih, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3425 S Bascom Ave., Ste 200, Campbell, CA 95008 Phone: 408-356-5292 Fax: 408-356-5307 | |
Dr. Shelley Marie Cowan, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 221 E Hacienda Ave Ste B, Campbell, CA 95008 Phone: 408-376-3350 Fax: 408-374-4130 |